Positive Harm-Benefit Data Found in PSA Screening for Black Patients With Prostate Cancer
May 15th 2022Complementary approaches to quantifying overdiagnosis generated a more beneficial harm-benefit tradeoff of prostate-specific antigen screening, compared with previous estimates that used shorter follow-up from the introduction of screening.
Read More
Nivolumab Plus Chemotherapy Improves Event-Free Survival in Resectable NSCLC
April 11th 2022The combination of nivolumab plus platinum-doublet chemotherapy led to a significant improvement in event-free survival compared with chemotherapy alone as neoadjuvant treatment in patients with resectable non–small cell lung cancer, according to findings from the phase 3 CheckMate 816 trial.
Read More
Elacestrant Significantly Improves PFS Over SOC in Advanced ER+ Metastatic Breast Cancer
March 5th 2022Elacestrant was found to result in a statistically significant and clinically meaningful improvement in progression-free survival over standard-of-care treatment in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who previously received CDK4/6 inhibitors.
Read More